

## Perspectivas actuales sobre el tratamiento de las miocardiopatías

Mohammed Ahmed Mustafa<sup>1</sup>, Ihsan Khudhair Jasim<sup>2,\*</sup>, Mohammed H. M<sup>3</sup>, Hussein Basim Furaij<sup>4</sup> and Hisham Ahmed Rashid Al-Saadi<sup>5</sup>

### Resumen

Las miocardiopatías constituyen un grupo heterogéneo de trastornos miocárdicos que producen anomalías estructurales y funcionales del corazón y representan una causa principal de insuficiencia cardíaca, arritmias y muerte súbita cardíaca a nivel mundial. Su creciente impacto clínico y epidemiológico ha impulsado avances sustanciales en las estrategias terapéuticas, que abarcan desde regímenes farmacológicos optimizados e intervenciones basadas en dispositivos hasta la ablación por catéter y el trasplante cardíaco. Paralelamente, modalidades emergentes como la terapia génica, los fármacos dirigidos a dianas moleculares y los tratamientos modificadores de la enfermedad para etiologías específicas (por ejemplo, formas sarcoméricas, inflamatorias o metabólicas) están redefiniendo el panorama terapéutico. Esta revisión sintetiza las perspectivas actuales sobre el tratamiento de las miocardiopatías hipertrófica, dilatada, restrictiva y arritmogénica del ventrículo derecho, con énfasis en la terapia médica guiada por las guías de práctica clínica, las indicaciones de los dispositivos implantables y el papel de las terapias avanzadas para la insuficiencia cardíaca. Se presta especial atención a la integración de la medicina de precisión, las herramientas de estratificación del riesgo y las rutas asistenciales multidisciplinarias, que en conjunto son fundamentales para individualizar el manejo y mejorar el pronóstico de los pacientes con estas complejas enfermedades miocárdicas.

Insuf Card 2024;19 (1): 3–12.

**Palabras clave:** Insuficiencia cardíaca, Medicina de precisión – Miocardiopatías

### Summary

#### *Current perspectives on the treatment of cardiomyopathies*

Cardiomyopathies comprise a heterogeneous group of myocardial disorders that lead to structural and functional cardiac abnormalities and are major contributors to heart failure, arrhythmias, and sudden cardiac death worldwide. Their growing clinical and epidemiological impact has driven substantial advances in therapeutic strategies, ranging from optimized pharmacological regimens and device-based interventions to catheter ablation and heart transplantation. In parallel, emerging modalities such as gene therapy, molecularly targeted agents, and disease-modifying treatments for specific etiologies (e.g., sarcomeric, inflammatory, or metabolic forms) are reshaping the therapeutic landscape. This review summarizes current perspectives on the treatment of hypertrophic, dilated, restrictive, and arrhythmogenic right ventricular cardiomyopathies, emphasizing guideline-directed medical therapy, indications for implantable devices, and the role of advanced heart failure therapies. Particular attention is given to the integration of precision medicine, risk stratification tools, and multidisciplinary care pathways, which together are crucial for individualizing management and improving outcomes in patients with these complex myocardial diseases.

**Keywords:** Cardiomyopathies, Heart failure, Precision medicine

<sup>1</sup>Department of Biology, College of Education, University of Samarra, Samarra, Iraq

<sup>2</sup>College of Pharmacy, Al-Turath University, Baghdad, Iraq

<sup>3</sup>Department of Medical Laboratory Technology, College of Health and Medical Techniques, Al-Bayan University, Iraq

<sup>4</sup>College of Pharmacy, University of Al-Ameed, Karbala, Iraq

<sup>5</sup>Al-Manara College for Medical Sciences, Maysan, Iraq

**Correspondencia:** Ihsan Khudhair Jasim. College of Pharmacy, Al-Turath University, Baghdad, Iraq.

E-mail: ihsan.khudhair@uoturath.edu.iq.

Recibido: 22/10/2024

Aceptado: 30/12/2024

## Introduction

Cardiomyopathies represent a diverse group of disorders affecting the heart muscle, impairing its ability to pump blood effectively and leading to significant morbidity and mortality on a global scale. These conditions are broadly classified into hypertrophic, dilated, restrictive, arrhythmogenic, and unclassified types, each distinguished by unique pathophysiological mechanisms and clinical features [1]. Advances in the molecular and genetic understanding of cardiomyopathies have transformed diagnostic and therapeutic approaches, offering new hope to patients and their families [2].

Genetic research has emerged as a cornerstone in the field, particularly in diagnosing hereditary forms of cardiomyopathies. The integration of genetic testing into clinical practice allows for early identification of at-risk family members, facilitating timely intervention and risk stratification [3]. These developments have been complemented by advancements in imaging technologies, such as cardiac magnetic resonance imaging (MRI), which provide detailed visualization of myocardial architecture and function [4]. Together, these innovations have significantly enhanced the precision of diagnosis and guided therapeutic decision-making tailored to the specific cardiomyopathy subtype.

The shift toward precision medicine has redefined therapeutic strategies in managing cardiomyopathies. For hypertrophic cardiomyopathy (HCM), pharmacological innovations such as myosin inhibitors have emerged as promising agents to alleviate symptoms and prevent disease progression [5]. In the management of dilated cardiomyopathy (DCM), advances in heart failure treatments, including angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors, have demonstrated significant improvements in patient outcomes [6]. Implantable devices, such as implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT), have also proven indispensable in preventing sudden cardiac death and improving quality of life [7].

Restrictive cardiomyopathies (RCM) present unique challenges due to their association with infiltrative and systemic diseases. Recent breakthroughs, such as the development of tafamidis for transthyretin amyloid cardiomyopathy, have marked a significant milestone in managing this condition, which was historically associated with a poor prognosis [8]. Similarly, advancements in arrhythmogenic right ventricular cardiomyopathy (ARVC) management, includ-

ing catheter ablation techniques and genetic-based therapies, underscore the ongoing innovation in this field [9]. Despite these advancements, significant disparities remain, particularly in low-resource settings where access to advanced diagnostics and therapies is limited [10, 11].

Understanding the underlying pathophysiology of cardiomyopathies is essential for effective management. These disorders are often driven by genetic mutations, metabolic imbalances, or environmental factors, such as exposure to toxins [12]. These factors can disrupt normal myocardial structure and function, leading to hypertrophy, fibrosis, or dilatation of the heart chambers. In some cases, abnormal electrical signaling may also occur, increasing the risk of arrhythmias and sudden cardiac death [13].

Cardiomyopathies are categorized into several distinct types based on their phenotypic expression and underlying causes:

1. *Hypertrophic Cardiomyopathy (HCM)*: Characterized by abnormal thickening of the ventricular walls, HCM is often caused by genetic mutations in sarcomeric proteins. This condition leads to impaired diastolic function and, in some cases, obstructive outflow, which can significantly impact patient outcomes [14].
2. *Dilated Cardiomyopathy (DCM)*: Defined by ventricular enlargement and reduced systolic function, DCM is linked to genetic, viral, or toxic etiologies. It commonly presents as heart failure with reduced ejection fraction and is a leading cause of heart transplantation worldwide [15].
3. *Restrictive Cardiomyopathy (RCM)*: This rare form of cardiomyopathy is marked by stiff ventricular walls, which limit diastolic filling. RCM is often associated with infiltrative diseases such as amyloidosis and sarcoidosis, underscoring the importance of disease-specific therapies [16].
4. *Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)*: ARVC involves the progressive replacement of right ventricular myocardium with fibrofatty tissue, leading to arrhythmias and an increased risk of sudden cardiac arrest. Genetic mutations play a central role in the development of this condition, emphasizing the importance of genetic counseling and testing [17].

**5. Unclassified Cardiomyopathies:** This category includes less common forms, such as left ventricular noncompaction, which do not fit neatly into the above classifications. These conditions remain an area of active research [18].

The increasing availability of diagnostic tools has revolutionized the management of cardiomyopathies. Imaging techniques, such as cardiac MRI, echocardiography, and nuclear imaging, allow for comprehensive assessment of myocardial structure and function [4]. These modalities are complemented by biomarkers, such as natriuretic peptides and cardiac troponins, which provide valuable insights into disease severity and prognosis. Furthermore, advances in molecular diagnostics have enabled the identification of novel therapeutic targets, paving the way for precision medicine [10].

While substantial progress has been made, significant challenges persist. Limited access to advanced diagnostic and therapeutic resources in low-income and middle-income countries continues to hinder global efforts to reduce the burden of cardiomyopathies. Additionally, the complex interplay of genetic and environmental factors in disease development remains an area of ongoing investigation. Addressing these challenges will require a concerted effort to bridge gaps in healthcare access and foster international collaboration in research and innovation.

This review aims to provide a comprehensive overview of the latest developments in the management of cardiomyopathies, highlighting the importance of an integrative approach that combines genetic, imaging, and therapeutic advancements. By exploring these advancements, this review underscores the potential for improving patient outcomes and reducing the global burden of cardiomyopathies [1, 2, 3, 4, 5, 6, 7, 8, 9, 10].

## Emerging Diagnostic Techniques in Cardiomyopathies

Recent advancements in diagnostic methods have revolutionized the identification and management of cardiomyopathies, a diverse group of myocardial disorders with complex etiologies. These innovations include state-of-the-art imaging modalities, genetic testing techniques, and computational tools that enhance precision in diagnosing the condition and provide deeper insights into its underlying mechanisms [19].

Medical imaging has undergone remarkable advancements, offering unparalleled insights into the

structural and functional alterations associated with cardiomyopathies. Among the most significant developments is the use of Cardiac Magnetic Resonance Imaging (CMR), which has emerged as the gold standard for assessing myocardial fibrosis, edema, and other structural abnormalities. Late gadolinium enhancement (LGE) imaging, a pivotal feature of CMR, enables the detection of scarring and fibrotic tissue, which are critical for risk stratification and prognostication in patients [20]. Similarly, Echocardiography with Strain Analysis has become a vital tool, employing speckle-tracking techniques to assess myocardial deformation. This method allows clinicians to detect early functional changes that may precede overt structural abnormalities, thereby facilitating timely intervention [21]. In addition, Positron Emission Tomography (PET) imaging has proven invaluable in identifying inflammatory or infiltrative cardiomyopathies, such as sarcoidosis, by visualizing metabolic activity in myocardial tissues [22]. Furthermore, advances in Computed Tomography (CT) have enhanced the detection of coronary artery anomalies, calcifications, and infiltrative diseases, offering a complementary perspective in diagnosing cardiomyopathies [23].

The integration of genetic testing into clinical practice has profoundly improved the understanding of inherited cardiomyopathies, enabling earlier and more accurate diagnoses. The advent of Next-Generation Sequencing (NGS) has facilitated the identification of pathogenic genetic mutations associated with specific cardiomyopathies, such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC). This approach has also allowed for family-based risk assessments and the implementation of preventive strategies in at-risk individuals [24]. Another emerging concept is Polygenic Risk Scoring, which evaluates multiple genetic variants to provide a comprehensive assessment of an individual's susceptibility to developing certain types of cardiomyopathies. This tool enhances our ability to understand disease predisposition and personalize patient management [25]. Advances in molecular biology have further led to the discovery of novel biomarkers, such as circulating microRNAs and specific troponin subtypes, which facilitate early detection, monitoring of disease progression, and response to therapy [26].

In addition to these developments, the integration of Artificial Intelligence (AI) and machine learning into diagnostic workflows is transforming the field. These computational tools analyze vast amounts of

imaging and genetic data, uncovering subtle patterns that may elude conventional diagnostic techniques. AI-driven algorithms have demonstrated the potential to improve diagnostic accuracy, enable personalized risk assessments, and guide therapeutic decision-making [27]. By combining advanced imaging technologies, genetic insights, and computational innovations, these emerging diagnostic techniques hold immense promise for improving the detection, management, and outcomes of cardiomyopathies.

### Pharmacological Advances in Cardiomyopathy Treatment

Recent pharmacological innovations have significantly transformed the management of cardiomyopathies, offering new avenues to improve heart function, mitigate symptoms, and enhance patient quality of life. These advances encompass novel drug therapies targeting the underlying pathophysiology of the disease, paving the way for more precise and effective treatments [28].

In the management of hypertrophic cardiomyopathy (HCM), recent developments have introduced innovative drugs like Mavacamten, a first-in-class cardiac myosin inhibitor. Mavacamten has shown remarkable efficacy in reducing left ventricular outflow tract (LVOT) obstruction and enhancing exercise capacity in patients with obstructive HCM [29]. Alongside this, traditional therapies such as beta-blockers (e.g., metoprolol) and calcium channel blockers (e.g., verapamil) remain pivotal in symptom management. However, newer agents like mavacamten are demonstrating superior outcomes, broadening therapeutic options for HCM patients [30].

For dilated cardiomyopathy (DCM), pharmacological advancements include the use of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) like sacubitril/valsartan. This combination has revolutionized the treatment of heart failure with reduced ejection fraction (HFrEF), improving survival rates and cardiac function in DCM patients [31]. Furthermore, Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors, such as dapagliflozin and empagliflozin, initially designed for managing diabetes, have exhibited significant cardioprotective effects. These drugs enhance left ventricular function and reduce hospitalizations due to heart failure, highlighting their utility in managing DCM [32].

Restrictive cardiomyopathy (RCM) has also benefited from pharmacological innovations. Tafamidis, approved for the treatment of transthyretin amyloidosis (ATTR), stabilizes the transthyretin pro-

tein, thereby slowing disease progression in patients with amyloid-related RCM [33]. Additionally, immunomodulatory therapies, including corticosteroids and immunosuppressive agents like methotrexate, are effective in reducing myocardial inflammation and fibrosis in RCM caused by sarcoidosis [34].

The treatment of arrhythmogenic cardiomyopathy (ACM) includes the use of Anti-arrhythmic Drugs, such as sotalol and amiodarone, to manage ventricular arrhythmias. Emerging research in gene-specific therapies is further expanding treatment possibilities. Early-stage studies on Gene Therapy, including gene-editing techniques like CRISPR/Cas9, aim to correct mutations responsible for ACM, offering potential curative options in the future [35, 36].

Finally, pharmacological research is exploring the role of Anti-fibrotic and Anti-inflammatory Drugs in managing cardiomyopathies. Pirfenidone, originally developed for pulmonary fibrosis, is under investigation for its ability to reduce myocardial fibrosis across various cardiomyopathies [37]. Similarly, Interleukin-1 (IL-1) Inhibitors, such as anakinra, are being studied for their potential in mitigating inflammatory cardiomyopathy and improving overall heart function [38].

These pharmacological advancements highlight the continuous evolution of cardiomyopathy management, providing clinicians with a diverse array of tools to address the complex pathophysiology of these disorders. By targeting disease-specific mechanisms and leveraging innovative therapeutic approaches, these developments promise to significantly enhance patient outcomes and quality of life.

### Role of Gene Therapy and Precision Medicine

The advent of gene therapy and precision medicine has revolutionized the management of inherited forms of cardiomyopathy, offering targeted treatments that address the root genetic causes of these conditions. These advanced approaches provide new hope for improved outcomes in disorders that were previously considered challenging to manage effectively [39].

Gene therapy involves introducing, removing, or altering genetic material within a patient's cells to correct or compensate for defective genes, and its recent advancements have opened transformative opportunities in the treatment of genetic cardiomyopathies. In hypertrophic cardiomyopathy (HCM), gene-editing technologies like CRISPR/Cas9 are being developed to target and repair mutations in sar-

comeric proteins, such as MYH7 and MYBPC3, which are commonly implicated in the condition. Preclinical studies have demonstrated promising results in preventing disease progression, marking a significant step forward in addressing the genetic basis of HCM [40]. Similarly, gene therapy approaches for dilated cardiomyopathy (DCM) focus on restoring function in genes like LMNA and TTN, which are associated with familial forms of the disease. Using viral vectors such as adeno-associated viruses (AAVs), corrective genetic material can be delivered directly to the myocardium, offering a targeted approach to managing DCM [41]. Research is also underway to develop gene therapies for arrhythmogenic cardiomyopathy (ACM), targeting mutations in desmosomal proteins such as PKP2. These therapies aim to stabilize the cardiac structure and prevent the fibrofatty replacement of myocardial tissue, addressing one of the key pathological features of ACM [42].

Precision medicine complements gene therapy by tailoring treatments to individual patients based on their unique genetic, molecular, and environmental profiles. This personalized approach has proven particularly impactful in the management of inherited cardiomyopathies. Advanced genetic screening tools enable the identification of pathogenic mutations, facilitating early diagnosis and risk stratification in asymptomatic family members of affected individuals [43]. Targeted pharmacological interventions are also being developed to address specific molecular pathways involved in genetic cardiomyopathies. For example, myosin inhibitors like mavacamten are designed for patients with HCM caused by sarcomeric protein mutations, offering a treatment option that aligns with the molecular underpinnings of the disease [44]. Additionally, the use of molecular biomarkers, such as circulating microRNAs and protein expression profiles, enhances the ability to select appropriate therapies and monitor treatment responses in real-time, ensuring a more dynamic and effective approach to disease management [45].

Emerging technologies in gene therapy are further enhancing the potential for treating genetic cardiomyopathies. Base editing, a novel technique, allows for precise modification of single nucleotide mutations without causing double-strand breaks, reducing the risk of off-target effects and increasing the safety and specificity of gene-editing interventions [46]. RNA-based therapies, including RNA interference (RNAi) and antisense oligonucleotides (ASOs), are also being explored to silence defective genes or modulate their expression, adding another layer of

versatility to the treatment arsenal for inherited cardiomyopathies [47].

Together, these advancements in gene therapy and precision medicine are transforming the landscape of cardiomyopathy management. By addressing the genetic and molecular basis of these conditions, these approaches hold the potential to significantly improve patient outcomes and set a new standard for personalized care in cardiovascular medicine.

## Device-Based Interventions: A New Era in Heart Failure Management

Device-based interventions have become a cornerstone in the management of advanced heart failure, particularly in cases associated with cardiomyopathies. These technologies offer mechanical and electrical support to improve cardiac function, prevent arrhythmias, and enhance patient survival. Among the most prominent interventions are pacemakers, implantable cardioverter defibrillators (ICDs), ventricular assist devices (VADs), and emerging technologies that aim to address the complex challenges of heart failure [48].

Pacemakers play a crucial role in managing bradycardias, which are common in certain types of cardiomyopathies. Dual-Chamber Pacemakers, for instance, maintain coordinated contractions between the atria and ventricles, thereby improving cardiac output in patients with conduction system diseases [49]. Another significant innovation in this area is Cardiac Resynchronization Therapy (CRT), which is designed for patients with heart failure and ventricular dyssynchrony, as frequently observed in dilated cardiomyopathy (DCM). By synchronizing ventricular contractions, CRT devices enhance the efficiency of the heart's pumping ability, alleviate symptoms, and reduce hospitalizations, making them a valuable tool in advanced heart failure management [50].

*Implantable Cardioverter Defibrillators (ICDs)* are equally vital in preventing sudden cardiac death in patients prone to life-threatening arrhythmias. For primary prevention, ICDs are implanted in individuals with a reduced ejection fraction or a high-risk genetic profile, such as those with arrhythmogenic cardiomyopathy. These devices play a preventive role by intervening before fatal arrhythmias occur [51]. In secondary prevention, ICDs deliver therapeutic shocks to terminate episodes of ventricular tachycardia or fibrillation, significantly reducing mortality in patients who have already survived a prior cardiac arrest [52].

*Ventricular Assist Devices (VADs)* provide mechanical support by assisting the heart in pumping blood from the ventricles to the rest of the body. Among these, Left Ventricular Assist Devices (LVADs) are particularly noteworthy, serving as a bridge to transplantation for patients with end-stage heart failure or as destination therapy for those who are ineligible for transplantation. LVADs have demonstrated significant improvements in both survival and quality of life, representing a transformative option for patients with advanced heart failure [53].

Emerging devices and technologies are further expanding the scope of device-based interventions in heart failure management. *Wearable Defibrillators*, for example, offer a non-invasive solution by monitoring and treating arrhythmias in high-risk patients who are not yet candidates for ICD implantation. These wearable devices provide a temporary and effective means of protection against sudden cardiac death [54]. Additionally, *Neuromodulation Devices*, such as vagus nerve stimulators, are being explored for their ability to target the autonomic nervous system. By modulating heart rate variability and autonomic function, these devices hold potential for improving outcomes in heart failure patients.

Overall, these device-based interventions represent a new era in the management of heart failure. By combining established technologies like pacemakers and ICDs with cutting-edge innovations such as wearable defibrillators and neuromodulation devices, clinicians now have an expanding arsenal of tools to address the complexities of heart failure and improve patient outcomes.

### Lifestyle Modifications and Non-Pharmacological Approaches

Lifestyle modifications are a fundamental component in the management of cardiomyopathies, serving as a crucial complement to pharmacological and device-based therapies. These interventions aim to reduce symptom burden, improve cardiac function, and enhance overall quality of life by addressing modifiable risk factors and promoting heart health [55].

Dietary changes play a pivotal role in managing cardiomyopathies. A *low-sodium diet* is particularly important for controlling blood pressure and preventing fluid retention, which can exacerbate heart failure symptoms [56]. Additionally, adopting a Mediterranean diet, which emphasizes the consumption of fruits, vegetables, whole grains, and healthy fats, has been associated with improved cardiovascular out-

comes and reduced systemic inflammation [57]. Patients with arrhythmogenic cardiomyopathies are advised to limit their intake of alcohol and caffeine, as excessive consumption of these substances can trigger arrhythmias and worsen their condition [58].

Regular physical activity, tailored to the patient's clinical status, is another cornerstone of non-pharmacological management. *Aerobic exercises* such as walking and cycling help improve overall heart function and endurance, while *resistance training* enhances muscle strength and metabolic health, particularly in individuals with reduced physical capacity. For patients recovering from acute cardiac events or surgeries, *supervised cardiac rehabilitation* programs provide a structured and safe environment for guided exercise, ensuring optimal recovery and risk reduction.

Stress management and psychological support are equally important in mitigating the impact of cardiomyopathies. Chronic stress and anxiety can exacerbate symptoms and negatively affect cardiovascular health. Techniques such as mindfulness meditation, yoga, and counseling services have been shown to improve mental well-being and reduce the physiological impact of stress on the heart. These interventions not only enhance quality of life but also contribute to better long-term cardiovascular outcomes.

Smoking cessation and weight management are vital lifestyle changes for patients with cardiomyopathies. Quitting smoking significantly reduces cardiovascular risk and slows the progression of the disease, while maintaining a healthy weight helps optimize cardiac function and enhances the effectiveness of other treatments. Together, these lifestyle modifications provide a comprehensive, non-pharmacological approach to managing cardiomyopathies, empowering patients to actively participate in their care and improve their overall health outcomes.

### Future Perspectives in Cardiomyopathy Research

Advances in cardiomyopathy research are rapidly reshaping the field, offering new opportunities and addressing significant challenges. Innovations in genetic and molecular research are at the forefront, with tools like CRISPR/Cas9 being refined to correct genetic mutations responsible for inherited cardiomyopathies. These advancements hold the promise of curative therapies by directly addressing the underlying genetic causes of the disease [55]. Simultaneously, the identification of novel molecular biomark-

ers is a key area of focus, enabling earlier detection, improved prognostic capabilities, and more precise monitoring of treatment responses [56].

Regenerative medicine also presents transformative possibilities for the management of cardiomyopathies. Research into *stem cell therapies*, including the use of cardiac stem cells and induced pluripotent stem cells (iPSCs), aims to regenerate damaged myocardium and restore cardiac function. These approaches offer hope for reversing disease progression rather than merely managing symptoms [57]. Additionally, advancements in tissue engineering are paving the way for the development of bioengineered heart tissues, which could replace or repair dysfunctional myocardium, providing a potential solution for patients with advanced heart failure [58].

The integration of *artificial intelligence (AI)* and big data analytics is revolutionizing the field of cardiomyopathy research. AI-driven algorithms are enabling the analysis of complex datasets, facilitating precision diagnostics, individualized treatment plans, and enhanced risk stratification. These tools are proving invaluable in identifying subtle patterns and correlations that may elude traditional analytical methods, thereby advancing both research and clinical practice.

Despite these promising developments, significant challenges remain. *Accessibility and cost* are major hurdles, as advanced therapies and diagnostic tools often come with high price tags, limiting their availability to broader populations. Efforts to make these innovations more affordable and accessible are essential to ensure equitable healthcare delivery. Additionally, ensuring the *long-term safety and efficacy* of novel interventions, particularly gene and cell-based therapies, is critical for their successful adoption in clinical practice. Rigorous clinical trials and ongoing surveillance will be necessary to address potential risks and refine these therapies.

The continued evolution of *personalized medicine* is expected to play a pivotal role in shaping the future of cardiomyopathy management. By integrating genetic, molecular, and clinical data, researchers and clinicians can refine treatment strategies to better address the unique needs of individual patients. This approach offers the potential for more effective, targeted, and patient-centric care, ushering in a new era of precision cardiology. As research progresses, these advances hold the promise of significantly improving outcomes and quality of life for patients with cardiomyopathies.

## Conclusion

Cardiomyopathies represent a complex and heterogeneous group of heart muscle disorders with significant implications for patient health and quality of life. Advances in understanding their pathophysiology and classification have paved the way for more precise diagnostic techniques and tailored therapeutic approaches. Innovations in medical imaging, genetic testing, pharmacological treatments, and device-based interventions have revolutionized the management of these conditions, offering new hope to patients. Moreover, the emergence of precision medicine and gene therapy highlights the potential for transformative, individualized care. Despite these advancements, challenges remain in making these therapies accessible and ensuring their long-term safety. Continued research in molecular mechanisms, regenerative medicine, and artificial intelligence promises to address these gaps and further enhance our ability to diagnose, treat, and prevent cardiomyopathies effectively. By integrating cutting-edge technologies with holistic patient care, the field is moving closer to achieving optimal outcomes for individuals affected by these challenging conditions.

## Referencias bibliográficas

- [1] Zhang, Yuanyuan, et al. "Application of biphenylene nanosheets for metronidazole detection." *Journal of Molecular Liquids* 398 (2024): 124216.
- [2] Thabet, Zahraa Fadel, and Heba A. Abd-Alsalam Al-salame. "Evaluation the Effectiveness of Nephelium lappaceum (NL) Peel Aqueous Extract Against Hepatocellular Carcinoma Induced by Thioacetamide (TAA) in Male Albino Rats." *Pure Sciences International Journal of Kerbala* 1.2 (2024).
- [3] Alex, John. "Atrial Fibrillation Management: The Combined Approach of Left Atrial Appendage Closure and Catheter Ablation." *Journal of Rare Cardiovascular Diseases* 4.8 (2024): 157-162.
- [4] Subramani, Raja, et al. "Advancements in 3D printing materials: A comparative analysis of performance and applications." *Applied Chemical Engineering* (2024): 3867-3867.
- [5] Asad, Nadeem, and Alejandro Schaffer. "Sustainable Aerospace Engineering: Biodegradable Polymers for Eco-Friendly 3D Printing Applications."
- [6] Santos, Diana Katherine Campoverde, et al. "Investigation of ORR and OER Mechanisms by Co-and Fe-doped Silicon Nanocages (Si48 and Si60) and Co-and Fe-doped Silicon Nanotubes (SiNT (5, 0) and SiNT (6, 0)) as Acceptable Catalysts." *Silicon* (2024): 1-13.

[7] Saadh, Mohamed J., et al. "Performances of nanotubes and nanocages as anodes in Na-ion battery, K-ion battery, and Mg-ion battery." *Ionics* 30.5 (2024): 2657-2664.

[8] Saadh, Mohamed J., et al. "Targeting hypoxic and acidic tumor microenvironment by nanoparticles: A review." *Journal of Drug Delivery Science and Technology* (2024): 105660.

[9] Raja, S., et al. "Surface functionalization of bio-based polymers in FDM: A pathway to enhanced material performance." *Applied Chemical Engineering* 7.3 (2024).

[10] Raja, S., et al. "Unlocking the potential of polymer 3D printed electronics: Challenges and solutions." *Applied Chemical Engineering* (2024): 3877-3877.

[11] Pura, Agnieszka, Marta Wilk, and Maria Olszowska. "Prognostic value of inflammatory markers in acute coronary syndrome in a population with premature cardiovascular disease (RCD code: VIII)." *Journal of Rare Cardiovascular Diseases* 4.2 (2019): 37-41.

[12] Prochwicz, Anna, Elżbieta Szczepanek, and Dorota Krochmalczyk. "Current views on the use of interferons in the treatment of polycythaemia vera (RCD code: VIII)." *Journal of Rare Cardiovascular Diseases* 4.2 (2019): 34-36.

[13] Dutt, Ateeet, et al. "Silicon compound nanomaterials: Exploring emission mechanisms and photobiological applications." *Advanced Photonics Research* 4.8 (2023): 2300054.

[14] Saadh, Mohamed J., et al. "Incorporation anthracene and Cu to NH<sub>2</sub>-Zr-UiO-67 metal-organic framework: Introducing the simultaneous selectivity and efficiency in photocatalytic CO<sub>2</sub> reduction to ethanol." *Journal of Molecular Structure* 1318 (2024): 139329.

[15] Mustafa, Mohammed Ahmed, et al. "A novel fuzzy M-transform technique for sustainable ground water level prediction." *Applied Geomatics* 16.1 (2024): 9-15.

[16] Mustafa, Mahbuba A., and Soran A. Othman. "Effect of adding natural and synthetic antioxidants to broiler drinking water as antistressor on productivity, antioxidant status and hematological traits under heat stress." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 94-104.

[17] Mustafa, Harith Ahmed, et al. "Isolation and Identification of Some Types of Pathogenic Bacteria from the Prepuce (Foreskin) of Circumcised Children in Samarra City/Iraq." *HIV Nursing* 22.2 (2022): 2776-2780.

[18] Mohammed, Arkan B., Oday K. Hamad, and Thamer A. Khttab. "Effect of zinc oxide nanoparticles in drinking water on growth rate, biochemical parameters, and intestinal histology of broilers." *Advances in Agriculture* 2023.1 (2023): 8523516.

[19] Mejía, Nora, et al. "Potential of Nanocages as Effective Catalysts for Oxygen Reduction Reaction." *Silicon* (2024): 1-8.

[20] Mahmood, Adnan, et al. "The Efficacy of Quinolones and Fluoroquinolones in the Medicine: A review study." *Iraqi Journal of Medical and Health Sciences* 1.1 (2024): 27-35.

[21] Kashkool, Marwah Jaafar, et al. "Some Mechanical Properties of Polymer Modified Concrete by Adding Waste Iron Filings and Chips." *Key Engineering Materials* 895 (2021): 110-120.

[22] Karim, Kamaran Khattab, and Nazim Rasul Abdulla. "Use of various sources of calcium in the diets of broiler and its effects on carcass and some meat quality." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 45-56.

[23] Kamil, Rasha Ali, et al. "Improvement of the mechanical properties of polymer-modified concrete by using PC superplasticizer." *Pollack Periodica* 18.3 (2023): 14-19.

[24] Kadhum, Hussam H., et al. "Potential pharmaceutical applications and molecular docking study for green fabricated ZnO nanoparticles mediated Raphanus sativus: In vitro and in vivo study." *Nanotechnology Reviews* 13.1 (2024): 20240113.

[25] Kadham, S. M., et al. (2023). "Comparison of fuzzy transforms in x-ray image processing." *International Journal of System Assurance Engineering and Management*.

[26] Kadham, Shaymaa Maki, et al. "IoT and artificial intelligence-based fuzzy-integral N-transform for sustainable groundwater management." *Applied Geomatics* 16.1 (2024): 1-8.

[27] Jawad, Zainab Nizar, Kamal Abdul Rasool, and Weaam Awad. "The relationship between smoking and Urokinase gene 3'-UTR T/C expression on occurrence of bladder cancer." *Indian Journal of Forensic Medicine & Toxicology* 14.1 (2020): 1169-1171.

[28] Jawad, Zainab Nizar, Zuhair Mohammed Ali Jeddoua, and Riadh Rasheed Al-Toama. "Association of MDM2 (T309G) gene polymorphism with interstitial urinary bladder cancer." *Biochemical & Cellular Archives* 18.2 (2018).

[29] Jawad, Zainab Nizar, and Weaam Awad. "The effect of montelukast on CD14 gene expression in asthmatic patient in Kerbala." *AIP Conference Proceedings*. Vol. 2290. No. 1. AIP Publishing, 2020.

[30] Jawad, Zainab Nizar, and Weaam Awad. "Association of urokinase and Vitamin D receptor genes SNPs and urolithiasis in an Iraqi population." *Meta Gene* 24 (2020): 100679.

[31] Jawad, Zainab Nizar, and Kamal AR. "Association of Additive Risk of Pioglitazone Use with the Presence of CYP1A1 Polymorphisms in the Occurrence of Bladder Cancer." *Systematic Reviews in Pharmacy* 11.5 (2020).

[32] Jawad, Zainab Nizar. "Association between APC gene SNPs and the risk of occurrence of colorectal cancer." *AIP Conference Proceedings*. Vol. 2414. No. 1. AIP Publishing, 2023.

[33] Jawad, Zainab Nizar. "Molecular detection of caspase 3, 8, 9 genes and ADIPOR1 (rs2275738) polymorphism in colorectal cancer." *Applied Nanoscience* 13.8 (2023): 5365-5368.

[34] Jawad, Zainab Nizar. "Molecular Diagnosis of CD14 and MnSOD Genes and their Effect on Asthma in Holy Karbala, Iraq." *Indian Journal of Public Health Research & Development* 10.8 (2019).

[35] Jawad, Zainab Nizar. "THE ASSOCIATION OF UROKINASE GENE 3'-UTR T/C POLYMORPHISM WITH URINARY BLADDER CANCER." *Biochemical & Cellular Archives* 18.1 (2018).

[36] Jalal, Bnar J., and Mustafa RM Alqaisi. "Improving the production and quality of white button mushroom (*Agaricus bisporus*) by adding biochar and ash to the casing layer." *Tikrit Journal for Agricultural Sciences* 24.1 (2024): 22-33.

[37] Hsu, Chou-Yi, et al. "Exploiting the immune system in hepatic tumor targeting: unleashing the potential of drugs, natural products, and nanoparticles." *Pathology-Research and Practice* (2024): 155266.

[38] Hsu, Chou-Yi, et al. "Amphiregulin in infectious diseases: Role, mechanism, and potential therapeutic targets." *Microbial Pathogenesis* 186 (2024): 106463.

[39] Hama Hasan, Torken Ahmed, et al. "Effect of *Equisetum Arvense* Phenolic Extract in Treatment of *Entamoeba Histolytica* Infection." *Systematic Reviews in Pharmacy* 11.11 (2020).

[40] George, Mike. "A Comprehensive Framework for Rare Disease Management in Primary Care." *Journal of Rare Cardiovascular Diseases* 4.8 (2024): 163-165.

[41] Fadhil, K. B., M. A. A. Majeed, and M. A. Mustafa. "Electronic study of fresh enzyme complexes of antifungal drugs-P450 and *Aspergillus* kojic acid biosynthesis. W: w saccharose flavus: fructose as a substratum." *Annals of Tropical Medicine and Health* 22 (2019): 65-72.

[42] Ortiz, Daniela Tatiana Castañeda, et al. "Exploring the photovoltaic performance of boron carbide quantum dots doped with heteroatoms: A DFT analysis." *Diamond and Related Materials* 143 (2024): 110933.

[43] Ali, Hala Abdullah, and Iktifaab Abdel Hamid. "Impact of Adropin, Adiponectin, and Insulin Variations in Type 2 Diabetes." *Journal of Primeasia* 5.1 (2024): 1-6.

[44] Alsalam, NHiba A., et al. "Protective Role of Alchoholic Extract of Fennel Seed in Nephrotoxicity Induced by Cisplatin in Male Rabbits." *Biochemical & Cellular Archives* 18 (2018).

[45] Alsalam, Heba A. Abd-Alsalam, and Layla S. Laylani. "Evolution the effectiveness of *Vernonia amygdalina* in some physiological parameters against hepatic and renal injury in male rats: Evaluating the Efficacy of *Vernonia amygdalina* on Physiological Parameters in Ameliorating Hepatic and Renal Injury in Male Rats." *Tikrit Journal for Agricultural Sciences* 24.2 (2024): 298-310.

[46] Alsalam, Heba A. Abd-Alsalam. "Study Effects of *Nigella Sativa* Seeds Oil in Some Physiological Parameters in Experimental Heart Failure Induced by Ivabradine in Male Rats." *Indian Journal of Forensic Medicine & Toxicology* 14.3 (2020): 2609-2613.

[47] Alsalam, Heba A. Abd-Alsalam. "Study the Effect of *Lycium barbarum* Polysaccharide on Bone and Thyroid Gland in Hyperlipidemic Healthy Male Albino Rats." *Scopus Ijphrd Citation Score* 10.7 (2019): 764.

[48] AL-qanbar, Mohammed Majid, Wefak Jbori AL-Bazi, and Hepa A. Abd-Alsalam. "The effect of Hyperhomocysteinemia on the Osteoclasts activity in Male New Zealand White Rabbits." *Research Journal of Pharmacy and Technology* 15.12 (2022): 5443-5448.

[49] Ali, Raghad Hassan, et al. "Assessment of Serum Cystatin C and Apolipoprotein Levels in Chronic Kidney Disease Patients." *Iraqi Journal of Medical and Health Sciences* 1.1 (2024): 8-13.

[50] Al-Bahrani, Hussein S., et al. "Determining new way to detect hydrocarbon polluted water at vertical and horizontal spaces." *Materials Today: Proceedings* 42 (2021): 2071-2075.

[51] Al-Abodi, Hiba Riyadh, et al. "Novel gold nanobiosensor platforms for rapid and inexpensive detection of *Vibrio cholerae*." *Reviews and Research in Medical Microbiology* 31.2 (2020): 70-74.

[52] Alabbasy, Raghad Hazem, et al. "Histological study of the effect of some oncology drugs on heart muscle." *AIP Conference Proceedings*. Vol. 2977. No. 1. AIP Publishing, 2023.

[53] AL-Aameli, Muna Hussain, Rajaa Ali Moheiseen Al-Taee, and H. A. Alsalam. "Histological & physiological alterations in the aorta & heart in relation with cholesterol diet in male albino rat." *Indian J. Forensic Med. Toxicol* 13 (2019): 313-318.

[54] Al-Omairi, Baida Ajeal Badir, and Len Nokes. "The Impact of Twisting on The Extent of Lower Lumbar Spine Lateral Flexion Among Healthy Subjects." *Iraqi Journal of Medical and Health Sciences* 1.1 (2024): 22-26.

[55] Abdulqader, Abeer T., Aseel Muthana Yousif Al-Sammarie, and Mohammed Ahmed Mustafa. "A comparative environmental study of aqueous extracts of ginger and grapes to protect hepatocytes in Albino rabbits and a comparison of extracts in preserving Awassi lamb meat from oxidation." *IOP Conference Series: Earth and Environmental Science*. Vol. 1029. No. 1. IOP Publishing, 2022.

[56] Abdulnabi, O. W., H. A. Alsalam, and M. N. Al-baiati. "Studying of Using Chitosan-Cephalexin Nano composed to Induce ROS and Apoptosis in Colon Cancer Cell Line HCT-29." *Moroccan Journal of Chemistry* 12.3 (2024): 1270-1280.

[57] Abdullah, Khalida Khalil, et al. "A comparative study of effect of Cymbopogon citratus aqueous extract and rosuvastatin on experimentally induced hyperlipidemia in local rabbits." *AIP Conference Proceedings*. Vol. 2394. No. 1. AIP Publishing, 2022.

[58] Abdulazeez, Maha Isam, et al. "Dental trauma of permanent incisor teeth in children/Kirkuk city." *Systematic Reviews in Pharmacy* 11.12 (2020).